Live Breaking News & Updates on Preventing Lipoprotein

 
Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease
- 
High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world s population 
 
 
LONDON,
 
Silence Therapeutics plc
, AIM:
SLN and Nasdaq: SLN
(
Silence

or

the Company
),
a leader in the discovery,
 
development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today
announced a new review publication on the prevention of cardiovascular disease linked to high lipoprotein(a) - Lp(a) - levels in the latest issue of Cardio ....

City Of , United Kingdom , Giles Campion , Daniel Adams Gary Clarence , Mallinckrodt Pharmaceuticals , Investec Bank , European Society Of Cardiology , Cardiovascular Research , Corporate Communications , Consilium Strategic Communications , Silence Therapeutics Announces Publication , Cardiovascular Research Highlighting , Emerging Potential , Preventing Lipoprotein , Mediated Cardiovascular Disease , Silence Therapeutics , European Society , Chief Medical Officer , Nominated Adviser , Angela Gray , நகரம் ஆஃப் , ஒன்றுபட்டது கிஂக்டம் , கில்ஸ் கேம்பியன் , டேனியல் ஆடம்ஸ் கேரி தெளிவு , ஐரோப்பிய சமூகம் ஆஃப் இருதயவியல் , இருதய ஆராய்ச்சி ,